Display Settings:

Format

Send to:

Choose Destination
    Trends Immunol. 2010 Sep;31(9):339-45. Epub 2010 Jul 23.

    New views on natural killer cell-based immunotherapy for melanoma treatment.

    Source

    Wellcome Trust Sanger Institute, Hinxton, Cambridge, UK.

    Abstract

    Natural killer (NK) cell-based immunotherapies treat hematopoietic malignancies, but are less effective against solid tumors. Here, we review recent data on NK cell recognition of melanoma at various stages of the disease and propose a combinatorial strategy to exploit fully the potential of NK cells. Depending on the stage of melanoma progression, NK cell-based therapies could be combined with pharmacological and T cell-based immunotherapies, to: (i) prevent lymph node metastases by redistributing cytotoxic NK cells; (ii) boost NK cell activity using chemotherapy to upregulate activating ligands on tumor cells; and (iii) target visceral metastases by transfer of autologous or allogeneic NK cells.

    Copyright (c) 2010 Elsevier Ltd. All rights reserved.

    PMID:
    20655806
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for Elsevier Science

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk